Curve Dental vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud dental practice management software offering an all-in-one platform for single offices and growing dental groups. Layton UT; founded 2004; one of the earliest true cloud dental PMS alternatives to legacy Dentrix and Eaglesoft; no local server required; covers scheduling, charting, imaging, and billing.
About
Curve Dental is a Layton, Utah-based cloud-based dental practice management software company that offers an all-in-one platform combining scheduling, clinical charting, digital imaging, billing, and patient communication in a single browser-based application. Founded in 2004, Curve was among the early movers in cloud dental practice management and has built a platform specifically for independent dental practices and small group practices that want a modern, easy-to-use alternative to legacy on-premise systems like Dentrix and Eaglesoft. Curve's cloud architecture means there is no local server to maintain, no software to install or update, and no data backup to manage—the entire system is accessed through a web browser from any device with an internet connection.\n\nCurve's integrated imaging capability—including digital X-ray sensor compatibility, intraoral camera support, and panoramic image management—is a key differentiator in the cloud practice management market, where many competitors require a separate imaging software. By managing clinical imaging and scheduling in the same platform, Curve eliminates the need to switch between systems during patient appointments and ensures that radiographs are automatically associated with the correct patient chart and treatment records. The platform's clinical charting module supports periodontal charting, treatment planning, electronic prescriptions, and clinical notes in a unified workflow designed for the pace of a busy dental office.\n\nCurve Dental competes with Dentrix Ascend (Henry Schein's cloud offering), Eaglesoft Cloud, Carestream, and Planet DDS's Denticon in the dental practice management market. The company targets single-office practices and small groups of up to 10 locations that want cloud convenience without the enterprise complexity of DSO-focused platforms. Curve differentiates on the all-in-one nature of its platform—imaging included at no additional cost—and the simplicity of its pricing and onboarding experience for practices transitioning from legacy systems.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.